RMD

From a fundamental perspective, ResMed demonstrates strong growth metrics, with an impressive revenue growth rate of 10.8% quarter-over-quarter and an extraordinary year-over-year revenue growth of 984.0%. The company boasts a robust gross margin of 5936.2% and an operating margin of 3274.9%. The price-to-earnings (P/E) ratio is currently at 18.2, with a forward P/E of 15.9, indicating that investors may be getting a reasonable valuation given the strong earnings per share (EPS) of $10.37 and a 10.5% EPS growth rate quarter-over-quarter. Analyst sentiment remains positive, with a consensus rating of "BUY" from 19 analysts, including 2 strong buys, and a target price averaging $262.20, suggesting a potential upside from the current price.

Currently, there are no earnings scheduled within the next 30 days, with the last quarter reported on March 31, 2026. Recent news has seen RMD's stock price decrease by 3.9% following a downgrade from Morgan Stanley, raising concerns about valuation despite its strong growth indicators. One key aspect to monitor moving forward is the company's ability to maintain its exceptional margins amid potential market headwinds, especially given the significant recent price target cut to $277.74, which still implies a substantial upside. Investors should watch for any changes in analyst sentiment or new developments regarding market conditions that could impact ResMed's performance in the coming months.